

Our Ref: 550/2021
June 2021

Re: Your request made under the Freedom of Information Act 2000

I have a Freedom of Information request and I would greatly appreciate if you could answer the below three questions:

Q1. Could you please provide the numbers of patients treated in the last 3 months by the **Dermatology** department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira **1**
- Adalimumab Biosimilar **19**
- Apremilast **0**
- Brodalumab **4**
- Certolizumab **0**
- Dimethyl fumarate **1**
- Etanercept – Enbrel **0**
- Etanercept Biosimilar **1**
- Guselkumab **12**
- Infliximab – Remicade **0**
- Infliximab Biosimilar **cannot separate from GI medical**
- Ixekizumab **0**
- Risankizumab **0**
- Secukinumab **51**
- Tildrakizumab **3**
- Ustekinumab **20**

Q2. For the patients treated by the Dermatology department in the last three months with any of the above drugs, can you please provide the total number of paediatric (up to age 16) versus adult patients? **0**

Q3. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira **14**
- Adalimumab Biosimilar **92**
- Golimumab **0**
- Infliximab – Remicade **0**
- Infliximab Biosimilar **cannot separate from dermatology**
- Tofacitinib **0**
- Ustekinumab **35**
- Vedolizumab **78**

Awaiting your response.